Publication date: Sep 17, 2023
SARS-CoV-2, a respiratory viral disease, is thought to have a more severe course in patients with malignancy and low immune systems. This prospective single-center study was conducted at the University of Health Sciences Dr. BehcE7et Uz Children’s Hospital from September 22 and December 31, 2021. Asymptomatic COVID-19 transmission rates were assessed using SARS-CoV-2 serology in patients with leukemia who had no history of COVID-19 infection. Among the 54 patients, 19 (35. 2%) were females and 35 (64. 8%) were males. The median age was 5. 5 years (min 6 months, max 17 years). Forty-nine (90. 5%) of the leukemia patients had acute lymphoblastic leukemia (ALL), while 5 (9. 5%) had acute myeloid leukemia (AML). Five of the 54 patients had a history of COVID-19 or contact with a positive person. SARS-CoV-2 IgG positivity was detected in 18 (36. 7%) of 49 patients with no history of COVID-19 infection. Leukemia patients have a high seroconversion for SARS-CoV-2 without showing any symptoms supporting the asymptomatic course of COVID-19 infection in this risk group.
| Concepts | Keywords |
|---|---|
| December | COVID-19 |
| Females | leukemia |
| Hospital | malignity |
| Leukemia | SARS-CoV-2 IgG |
| Viral | serology |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | seroconversion |
| disease | MESH | leukemia |
| disease | MESH | viral disease |
| disease | MESH | malignancy |
| disease | IDO | history |
| disease | MESH | infection |
| disease | MESH | acute lymphoblastic leukemia |
| disease | MESH | acute myeloid leukemia |
| pathway | KEGG | Acute myeloid leukemia |